Abstract
Aspirin is an anti-inflammatory drug, and has been widely used for the prevention of cardio-cerebrovascular events. Matrix metalloproteinase (MMP)-2 and MMP-9 can degrade the extracellular matrix and may be critical for the development and disruption of atherosclerotic plaques, while tissue inhibitor of metalloproteinase (TIMP)-1 may inhibit the degradation of extracellular matrix. The purpose of present study was to investigate the inhibitory effects of aspirin on MMP-2 and MMP-9 expression and activity in cultured mouse celiac macrophages, and to determine the possible mechanisms. The results showed that MMP-2/9 mRNA expression and release were significantly decreased after cultured mouse celiac macrophages were treated with aspirin 12.5–50 μg/ml for 24 h, while the TIMP-1 mRNA expression and release, and peroxisome proliferator-activated receptor (PPAR) α/γ mRNA expression were increased after the same treatment. Moreover the aspirin-induced down-regulation of MMP-2/9 mRNA expression and reduction of MMP-9 release were notably alleviated after pretreatment with specific inhibitors of PPARα/γ. These results suggested that aspirin could inhibit the expression and release of MMP-2/9 by up-regulation of PPARα/γ gene expression, and also inhibit the activity of MMP-2/9 by induction of TIMP-1 expression, which might be good for the stabilization of atherosclerotic plaques and the prevention of cardio-cerebrovascular events.
Similar content being viewed by others
References
Libby, P. 2002. Inflammation in atherosclerosis. Nature 420:868–874. doi:10.1038/nature01323.
Shah, P. K. 1998. Role of inflammation and metalloproteinases in plaque disruption and thrombosis. Vasc. Med. 3:199–206.
Dollery, C. M., J. R. McEwan, and A. M. Henney. 1995. Matrix metalloproteinases and cardiovascular disease. Circ. Res. 77:863–868.
Galis, Z. S., and J. J. Khatri. 2002. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res. 90:251–262.
Galis, Z. S., C. Johnson, D. Godin, R. Magid, J. M. Shipley, R. M. Senior, and E. Ivan. 2002. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ. Res. 91:852–859. doi:10.1161/01.RES.0000041036.86977.14.
Cho, A., and M. A. Reidy. 2002. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ. Res. 91:845–851. doi:10.1161/01.RES.0000040420.17366.2E.
Ezzahiri, R., F. R. Stassen, H. A. Kurvers, M. M. van Pul, P. J. Kitslaar, and C. A. Bruggeman. 2003. Chlamydia pneumoniae infection induces an unstable atherosclerotic plaque phenotype in LDL-receptor, ApoE double knockout mice. Eur. J. Vasc. Endovasc. Surg. 26:88–95. doi:10.1053/ejvs.2002.1913.
Nishimura, K., M. Ikebuchi, Y. Kanaoka, S. Ohgi, E. Ueta, E. Nanba, and H. Ito. 2003. Relationships between matrix metalloproteinases and tissue inhibitor of metalloproteinases in the wall of abdominal aortic aneurysms. Int. Angiol. 22:229–238.
Auge, N., F. Maupas-Schwalm, M. Elbaz, J. C. Thiers, A. Waysbort, S. Itohara, H. W. Krell, R. Salvayre, and A. Negre-Salvayre. 2004. Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation of the sphingomyelin/ceramide pathway and smooth muscle cell proliferation. Circulation. 110:571–578. doi:10.1161/01.CIR.0000136995.83451.1D.
Zaltsman, A. B., S. J. George, and A. C. Newby. 1999. Increased secretion of tissue inhibitors of metalloproteinases 1 and 2 from the aortas of cholesterol fed rabbits partially counterbalances increased metalloproteinase activity. Arterioscler. Thromb. Vasc. Biol. 19:1700–1707.
Vincenti, M. P. 2001. The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes. Transcriptional and posttranscriptional regulation, signal transduction and cell-type-specific expression. Methods Mol. Biol. 151:121–148.
Blanquart, C., O. Barbier, J. C. Fruchart, B. Staels, and C. Glineur. 2003. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J. Steroid Biochem. Mol. Biol. 85:267–273. doi:10.1016/S0960-0760(03)00214-0.
Marx, N., H. Duez, J. C. Fruchart, and F. Staels. 2004. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ. Res. 94:1168–1178. doi:10.1161/01.RES.0000127122.22685.0A.
Ringseis, R., N. Schulz, D. Saal, and K. Eder. 2008. Troglitazone but not conjugated linoleic acid reduces gene expression and activity of matrix-metalloproteinases-2 and -9 in PMA-differentiated THP-1 macrophages. J. Nutr. Biochem. 19:594–603. doi:10.1016/j.jnutbio.2007.08.003.
Hanefeld, M., N. Marx, A. Pfutzner, W. Baurecht, G. Lubben, E. Karagiannis, U. Stier, and T. Forst. 2007. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the piostat study. J. Am. Coll. Cardiol. 49:290–297. doi:10.1016/j.jacc.2006.08.054.
Marfella, R., M. D’Amico, C. D. Filippo, A. Baldi, M. Siniscalchi, F. C. Sasso, M. Portoghese, O. Carbonara, B. Crescenzi, P. Sangiuolo, G. F. Nicoletti, R. Rossiello, F. Ferraraccio, F. Cacciapuoti, M. Verza, L. Coppola, F. Rossi, and G. Paolisso. 2006. Increased activity of the ubiquitin–proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque effects of rosiglitazone treatment. J. Am. Coll. Cardiol. 47:2444–2455. doi:10.1016/j.jacc.2006.01.073.
Mehta, P. 2002. Aspirin in the prophylaxis of coronary artery disease. Curr. Opin. Cardiol. 17:552–558. doi:10.1097/00001573-200209000-00017.
Akaike, M., H. Azuma, A. Kagawa, K. Matsumoto, I. Hayashi, K. Tamura, T. Nishiuchi, T. Iuchi, N. Takamori, K. Aihara, T. Yoshida, Y. Kanagawa, and T. Matsumoto. 2002. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin. Chem. 48:1454–1459.
Ranga, G. S., O. P. Kalra, H. Tandon, J. K. Gambhir, and G. Mehrotra. 2007. Effect of aspirin on lipoprotein(a) in patients with ischemic stroke. J. Stroke Cerebrovasc. Dis. 16:220–224. doi:10.1016/j.jstrokecerebrovasdis.2007.05.003.
Vinals, M., I. Bermudez, G. Llaverias, M. Alegret, R. M. Sanchez, M. Vazquez-Carrera, and J. C. Laguna. 2005. Aspirin increases CD36, SR-BI, and ABCA1 expression in human THP-1 macrophages. Cardiovasc. Res. 66:141–149. doi:10.1016/j.cardiores.2004.12.024.
Karna, E., and J. A. Palka. 2002. Inhibitory effect of acetylsalicylic acid on metalloproteinase activity in human lung adenocarcinoma at different stages of differentiation. Eur. J. Pharmacol. 443:1–6. doi:10.1016/S0014-2999(02)01557-1.
Murono, S., T. Yoshizaki, H. Sato, H. Takeshita, M. Furukawa, and J. S. Pagano. 2000. Aspirin inhibits tumor cell invasiveness induced by Epstein–Barr virus latent membrane protein-1 through suppression of matrix metalloproteinase-9 expression. Cancer Res. 60:2555–2561.
Jiang, M. C., C. F. Liao, and P. H. Lee. 2001. Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. Biochem. Biophys. Res. Commun. 282:671–677. doi:10.1006/bbrc.2001.4637.
Xue, J., Y. N. Hua, Z. L. Gu, K. Y. Wu, and M. L. Xie. 2008. Study of aspirin on inhibiting the atherosclerotic plaque rupture and MMP-2 expression of abdominal aorta in atherosclerotic rabbits. Chin. Pharmacol. Bull. 24(10):1335–1339.
Hua, Y. N., J. Xue, F. Sun, L. J. Zhu, and M. L. Xie. 2008. Aspirin inhibits MMP-2 and MMP-9 expressions and activities through upregulation of PPAR α/γ and TIMP gene expressions in ox-LDL-stimulated macrophages derived from human monocytes. Pharmacology 83:18–25. doi:10.1159/000166183.
Saiki, I., and I. J. Fidler. 1985. Synergistic activation by recombinant mouse IFN-gmma and muramyl dipeptide of tumoricidal properties in mouse macrophages. J. Immunol. 135:684–688.
Pillinger, M. H., P. B. Rosenthal, S. N. Tolani, B. Apsel, V. Dinsell, J. Greenberg, E. S. L. Chan, P. F. Gomez, and S. B. Abramson. 2003. Cyclooxygenase-2-derived E prostaglandins down-regulate matrix metalloproteinase-1 expression in fibroblast-like synoviocytes via inhibition of extracellular signal-regulated kinase activation. J. Immunol. 171:6080–6089.
Orbe, J., L. Fernandez, J. A. Rodriguez, G. Rabago, M. Belzunce, A. Monasterio, C. Roncal, and J. A. Paramo. 2003. Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. Atherosclerosis 170:269–276. doi:10.1016/S0021-9150(03)00251-X.
Rouis, M., C. Adamy, N. Duverger, P. Lesnik, P. Horellou, M. Moreau, F. Emmanuel, J. M. Caillaud, P. M. Laplaud, C. Dachet, and M. J. Chapman. 1999. Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. Circulation 100:533–540.
Allaire, E., R. Forgough, M. Clowes, B. Starcher, and A. W. Clowes. 1998. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. J. Clin. Invest. 102:1413–1420. doi:10.1172/JCI2909.
Lemaitre, V., P. D. Soloway, and J. D’Armiento. 2003. Increased medial degradation with pseudo-aneurysm formation in apolipoprotein E-knockout mice deficient in tissue inhibitor of metalloproteinases-1. Circulation 107:333–338. doi:10.1161/01.CIR.0000044915.37074.5C.
Clark, I. M., T. E. Swingler, C. L. Sampieri, and D. R. Edwards. 2008. The regulation of matrix metalloproteinases and their inhibitors. Int. J. Biochem. Cell. Biol. 40:1362–1378. doi:10.1016/j.biocel.2007.12.006.
Kopp, E., and S. Ghosh. 1994. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265:956–959. doi:10.1126/science.8052854.
Acknowledgments
This work was supported by grants from the Natural Science Foundation of Jiangsu Province (No. BK2005029), People’s Republic of China.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yiqin, Y., Meilin, X., Jie, X. et al. Aspirin Inhibits MMP-2 and MMP-9 Expression and Activity Through PPARα/γ and TIMP-1-Mediated Mechanisms in Cultured Mouse Celiac Macrophages. Inflammation 32, 233–241 (2009). https://doi.org/10.1007/s10753-009-9125-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10753-009-9125-3